# Tectonic Therapeutic Inc. (TECX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $30.75, market value $601 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Tectonic Therapeutic Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.5×**. The shares trade at 2.5× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -12.0%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -29.5%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 40.7%**. Earnings per share rose 40.7%.

## Financial health
- **Debt to equity: 0.06**. Debt is 0.06 times equity: a conservative balance sheet.
- **Current ratio: 26.63** (quick 26.63). Current assets cover the next year's liabilities 26.63 times.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Tectonic Therapeutic Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Tectonic Therapeutic Inc.; the consensus is strong_buy, with an average price target of $77.56 (+152% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 78.1%** (YTD 47.4%, 3-mo 6.0%). The shares are up 78.1% over twelve months including dividends.
- **From 52-week high: -22.2%** (113.7% above the low). Trading 22% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 44**. An RSI of 44 is neutral.
- **Beta (1 yr): 1.21** (volatility 76%). Beta of 1.21 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TECX · Page: https://foliofundamentals.com/stocks/tecx

Not investment advice.